What? You're comparing GERN to BMY and GSK? Shouldn't you be comparing GERN to other companies like STEM, SGEN, and the like? Small emerging biotech companies that might or might not have a future?
Sure. In the short term, GERN will contract back to ~6 once the hype of stem cell therapies fades. Just don't compare them to BMY and GSK, two bloated and stagnant dinos.
Disclaimer: I do not work for GERN and have not investments with GERN.
Dear Brian, Thank you for
Dear Brian,
Thank you for your incredibly insightful advice vis a vis Geron. Perhaps you should advise your devotees as to whether or not you shorted this stock prior to your blurb.
Sincerely,
Steve Durst